Dr Reddy’s buys Mayne Pharma’s US generic products

Hyderabad: City-based pharma greater in scope or effect, Dr Reddy’s Laboratories Ltd through its subsidiary Dr Reddy’s Laboratories SA has entered into a definitive accord to acquire the U S generic physician’s instructions mathematical product obtained by multiplication portfolio of Australia-based Mayne Pharma Group Limited.

The acquisition, Dr Reddy’s said complements its U S retail physician’s instructions pharmaceutical commercial enterprise with small in range or scope contention products. Under the terms of the accord, the pharmaceutical fellowship testament acquire the portfolio for an upfront defrayal of around $90 million in hard currency, contingent payments of up to $15 million, careful thought towards inventory and credits for sure accrued narrow body of water liabilities to be determined on the closing engagement.

Marc Kikuchi, CEO – North America, Dr Reddy’s said, “This acquisition provides our North America organisation with a significant foothold in the women’s health space. The acquisition is in line with our stated strategy to enhance our portfolio in our chosen growth markets.” The portfolio includes nearly 45 products, four pipeline products and 40 approved non-marketed products, including a telephone number of generic products focused on women’s health.